May 30 (Reuters) - Bristol Myers Squibb ( BMY ) said on

Thursday the U.S. FDA had allowed expanded use of its cell

therapy, Breyanzi, for an aggressive and rare type of blood

cancer.

The therapy was approved for patients with mantle cell

lymphoma (MCL), whose cancer has returned or stopped responding

to previous therapies.

Breyanzi belongs to a class of treatments known as CAR-Ts

and works by modifying white blood cells or T-cells to attack

cancer.

Like other CAR-T therapies, Breyanzi comes with a serious

warning about the risk of secondary malignancies, or cancers, in

patients who use the drug.